AVITA Medical Earnings Call Transcripts
Fiscal Year 2026
-
Interim results from the Cohealyx-I study show a significant reduction in time to grafting, with a mean of 13.6 days versus 33 days for traditional matrices. Surgeons report high satisfaction, workflow integration, and anticipate broader adoption due to improved outcomes and cost efficiency.
-
The company is targeting deeper penetration in acute wound care with three synergistic products, expecting sequential growth and improved margins as reimbursement normalizes and VAC approvals expand. Ongoing clinical studies and a data-driven approach support further adoption and profitability.
-
Disciplined execution and cost control have positioned the business for 2026 revenue growth, with guidance set at $80–$85 million and a focus on expanding product adoption. New credit facilities and resolved reimbursement issues provide stability, while operational priorities remain on revenue growth and profitability.
-
The presentation highlighted a focus on patient care, clinical innovation, and economic value, with RECELL and related products driving improved outcomes and cost savings. 2026 guidance projects $80–$85 million in revenue, supported by enhanced forecasting, cost control, and a targeted commercial strategy.
Fiscal Year 2025
-
Revenue grew 11% in 2025 to $71.6M, with Q4 at $17.6M and gross margin above 80%. 2026 guidance targets $80–$85M, driven by normalized RECELL utilization and expanded use of Cohealyx and PermeaDerm, supported by improved cost control and a flexible new credit facility.
-
Acute wound care products, led by RECELL, are driving shorter hospital stays and improved outcomes, but 2025 was challenged by reimbursement delays, causing revenue headwinds. With cost reductions, renewed commercial focus, and reimbursement progress, growth and profitability are targeted for 2026.
-
Focus is on expanding product utilization in key U.S. centers, restoring growth after reimbursement delays, and maintaining operational discipline. Clinical and economic benefits drive adoption, with international expansion in early stages. Leadership commits to transparency and predictable guidance.
-
Q3 revenue declined 13% year-over-year due to reimbursement disruptions, prompting a downward revision of 2025 guidance to $70–$74 million. All MACs have now published reimbursement rates, restoring provider confidence and setting the stage for renewed growth, with cost controls improving margins and cash use.
-
RECELL's spray-on skin technology delivers a 36% reduction in hospital stay for burn patients, driving significant cost savings and faster recovery. The company is expanding its acute wound care portfolio, optimizing its commercial model, and resolving reimbursement challenges, with profitability expected by mid-2026.
-
Q2 revenue grew 21% year-over-year to $18.4M, but reimbursement delays reduced RECELL demand by 20% in H1. Guidance was lowered, but payment issues are resolving, and a strong H2 rebound is expected, with new business models and product launches supporting growth.
-
A major transformation has expanded the acute wound care portfolio, driving a $3.5B U.S. market opportunity and 47% CAGR, with profitability expected in Q4 2025. New products, strong clinical evidence, and operational efficiencies position the company for sustained growth and cash generation.
-
Q1 2025 revenue rose 67% year-over-year, driven by new product launches and portfolio expansion. Gross margin remained strong, and operational efficiencies are expected to reduce expenses by $2.5 million per quarter. Guidance for 2025 was reiterated, with profitability targeted for Q4.
-
A major portfolio expansion is driving a shift to therapeutic acute wound care, with new products like RECELL GO, PermeaDerm, and Cohealyx targeting burns, trauma, and surgical wounds. The addressable market has grown to $3.5 billion, with 2025 guidance projecting 55–65% revenue growth and profitability in Q4.
-
Acute wound care focus and expanded product portfolio have increased the addressable market to $3.5 billion, with strong adoption in U.S. burn and trauma centers. 2025 guidance targets $100M-$106M revenue, free cash flow in H2, and GAAP profitability in Q4, supported by new product launches and operational efficiencies.
-
A broad-based acute wound care strategy is driving rapid portfolio expansion, with RECELL GO, PermeaDerm, and Cohealyx offering clinical and economic advantages. The addressable market has grown to $3.5 billion, with 2025 guidance projecting strong revenue growth and profitability.
Fiscal Year 2024
-
Revenue grew 29% in 2024, driven by RECELL GO adoption and new trauma center accounts. 2025 guidance projects 55–65% revenue growth, with major contributions expected from Cohealyx and RECELL GO mini. Free cash flow and GAAP profitability are targeted for late 2025.
-
RECELL GO automation and new product launches are transforming the business into a broad acute wound care provider, expanding the addressable market and driving strong adoption. Margin stability, portfolio diversification, and a focus on profitability are key, with significant growth expected in 2024-2026.
-
RECELL GO adoption is accelerating, with 75% of revenue base converted and full transition expected by year-end. Revenue guidance for 2024 is reaffirmed at $68–$70 million, and profitability is targeted for Q3 2025. Market expansion and new products are set to drive significant growth.
-
Q3 revenue surged 44% year-over-year to $19.5M, driven by rapid RECELL GO adoption and expanded accounts. Gross margin remained strong, and new product launches plus international expansion are set to fuel further growth, with profitability targeted for Q3 2025.
-
A strategic transformation is underway, with automation, portfolio expansion, and global distribution driving growth. Key product launches and regulatory milestones are expected by early 2025, supporting a path to profitability and significant revenue growth.
-
Significant strategic transformation is underway, highlighted by the launch of RECELL GO and expansion into new indications and international markets. Q2 revenue grew 29% year-over-year, with profitability targeted for Q3 2025, supported by high gross margins and stable expenses.
-
Q2 2024 revenue grew 29% year-over-year to $15.1M, driven by RECELL GO and PermeaDerm launches. Gross margin rose to 86.2%, but net loss widened to $15.4M. Revised 2024 revenue guidance is $68–$70M, with strong growth expected from new products and international expansion.